Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for CABG Surgery

Not Applicable

• Conditions: CABG Surgery
• Interventions: Drug: Intravenous Crystalloid; Drug: Intravenous HES

• Registration Number: NCT02757027
• Lead Sponsor: Konkuk University Medical Center

Brief Summary

After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing CABG surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15).

All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number).

According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture.

Patient data and statistical analyses:

Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge.

All statistical analyses will be performed after the 30th patient's discharge and data acquisition

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-04
• Study First Submitted: 2016-04-27
• Study First Submitted QC: 2016-04-28
• Last Update Submitted: 2016-04-28
• Study First Posted: 2016-04-29
• Last Update Posted: 2016-04-29
• Study Start: 2016-05
• Primary Completion: 2016-10
• Study Completion: 2017-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients undergoing CABG Surgery
• Patients provided a written informed consent.
• Patients with preoperative serum hemoglobin concentration >13 g/dL (male) and >12 g/dL (female)
• Patients with PaO2/FiO2 ratio >150

Exclusion Criteria

• Patients with history of anemia, dyspnea, active infection.
• Patients with endocrine disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intravenous Crystalloid	Intravenous Crystalloid	crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Intravenous HES	Intravenous HES	HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

Primary Outcome Measures

Name	Time	Method
whole blood viscosity	with 1 hour after the completion of procedure	whole blood viscosity measured by viscometer cm-1

Secondary Outcome Measures

Name	Time	Method
glucose	with 1 hour after the completion of procedure	serum glucose level, g/dl
urine output	with 1 hour after the completion of procedure	hourly urine output, ml/hr
PaO2/FiO2 ratio	with 1 hour after the completion of procedure	PaO2/FiO2 ratio measured by arterial blood gas analysis
hematocrit	with 1 hour after the completion of procedure	serum hematocrit, %
osmolarity	with 1 hour after the completion of procedure	serum osmolarity, mOsm
Maximum clot formation	with 1 hour after the completion of procedure	Maximum clot formation in rotational thromboelastometry (ROTEM) analysis, mm